ABT-122: Phase I data

A double-blind, placebo-controlled Phase I trial in 64 healthy volunteers showed that single doses of 0.1, 0.3, 1, 3 and 10 mg/kg IV ABT-122 and 0.3, 1 and 3 mg/kg subcutaneous ABT-122 led to no serio...